SCHEMBL6924040

SCHEMBL6924040

CNC(=O)Oc1ccc(F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.51
FAAH O00519 3/20 0.51
KDM4E B2RXH2 3/20 0.51
CYP1A2 P05177 3/20 0.51
HPGD P15428 2/20 0.51
ACHE P22303 2/20 0.44
PGR P06401 1/20 0.44
GAA P10253 1/20 0.44
PTGS1 P23219 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
ADAMTS4 O75173 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP14 P50281 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12893245 0.89 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDACHEPGR
SCHEMBL22289601 0.86 ALDH1A1 (0.48) ALDH1A1FAAHKDM4ECYP1A2HPGD
SCHEMBL14783522 0.83 FAAH (0.50) ALDH1A1FAAHKDM4ECYP1A2HPGD
SCHEMBL2182880 0.81 LMNA (0.59) ALDH1A1KDM4ECYP1A2HPGDACHE
SCHEMBL9326191 0.81 SMN1; SMN2 (0.59) ALDH1A1CYP1A2HPGDGAANPC1
SCHEMBL27513052 0.81 KDM4E (0.53) ALDH1A1KDM4EHPGDACHEPGR
SCHEMBL10277072 0.81 FAAH (0.49) ALDH1A1FAAHKDM4ECYP1A2HPGD
SCHEMBL28962581 0.80 ALDH1A1 (0.53) ALDH1A1FAAHKDM4ECYP1A2HPGD
SCHEMBL188010 0.79 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL11599136 0.79 ALDH1A1 (0.45) ALDH1A1KDM4ECYP1A2HPGDACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3784669-B1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMA (US) 2023-10-25 EP disclosed
EP-2513052-B1 PYRROLIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-06-04 EP disclosed
US-8263762-B2 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists DOGWOOD PHARMACEUTICALS, INC. (US) 2012-09-11 US disclosed
US-8063021-B2 Ketolide anti-infective compounds KOSAN BIOSCIENCES INCORPORATED (US) 2011-11-22 US disclosed
EP-2374455-A2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-10-12 EP disclosed
EP-2364705-A2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-14 EP disclosed
WO-2011085886-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-21 WO disclosed
US-20110144081-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 US disclosed
US-20110003766-A1 ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS ADENOSINE THERAPEUTICS, LLC 2011-01-06 US disclosed
US-7365196-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK SHARP & DOHME LTD. (GB) 2008-04-29 US disclosed
CN-1993117-A Hydroxyalkyl amide compounds HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144081-A1 PYRROLIDINE DERIVATIVES TACR1, OPRL1, SLC6A3 ALDH1A1 747/4885FAAH 2194/4885KDM4E 1636/4885
US-20110003766-A1 ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS ADORA2A, ADORA3, ADORA1 ALDH1A1 431/4885FAAH 870/4885KDM4E 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.